Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Piperacillin/tazobactam is associated with drug-induced thrombocytopenia (DITP), a severe hematologic complication.
• The mechanism involves a humoral immune response triggered by piperacillin/tazobactam binding to platelet proteins.
• Cross-reactivity among beta-lactam antibiotics is a concern due to structural similarities, but the specific immunogenic moiety is unknown.

Purpose of the Study:

• To investigate the potential for cross-reactivity in piperacillin/tazobactam-induced thrombocytopenia.
• To evaluate the safety of alternative beta-lactam antibiotics in patients with piperacillin/tazobactam DITP.
• To highlight the need for further research into the structure-activity relationship of DITP caused by beta-lactams.

Main Methods:

• Case report of a patient with piperacillin/tazobactam DITP.
• Successful treatment challenge with cefepime for aspiration pneumonia.
• Review of existing literature on beta-lactam induced thrombocytopenia and cross-reactivity.

Main Results:

• The first reported case of piperacillin/tazobactam DITP successfully managed with cefepime.
• Cefepime administration did not exacerbate thrombocytopenia in this patient.
• This suggests potential tolerance or lack of cross-reactivity between piperacillin/tazobactam and cefepime in DITP.

Conclusions:

• Cefepime may be a safe alternative in patients with piperacillin/tazobactam-induced thrombocytopenia.
• Further studies are required to elucidate the specific structural components of piperacillin/tazobactam responsible for DITP.
• Evaluating the safety and cross-reactivity of other beta-lactam antibiotics is crucial for clinical practice.